Trials / Completed
CompletedNCT06717425
A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE-RANGING STUDY OF PF-07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 263 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07976016) for the potential treatment of obesity. The study will compare the experiences of participants taking the study medicine (PF-07976016) to those of participants who take placebo (a lookalike substance that contains no active study medicine). The aim is to measure the body's response to the study medicine, including any changes in participants' body weight and how well they tolerate the study medicine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-07976016 | Taken once daily |
| DRUG | Placebo | Taken once daily |
Timeline
- Start date
- 2024-12-09
- Primary completion
- 2025-10-23
- Completion
- 2026-01-12
- First posted
- 2024-12-05
- Last updated
- 2026-02-06
Locations
38 sites across 3 countries: United States, Canada, Poland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06717425. Inclusion in this directory is not an endorsement.